EPFL spinout MindMaze has raised $105m from investors including AlbaCore Capital, which had supplied $125m in capital only four months ago.
MindMaze, a Switzerland-based digital neurotherapeutics platform spun out of EPFL, received $105m in a funding round on Thursday led by private equity firm Concord Health Partners.
The round also featured AlbaCore Capital, Hambro Perks and several unnamed family offices. Although an updated valuation was not disclosed, MindMaze is worth at least $1.5bn.
Founded in 2012, MindMaze has built a digital health platform using technologies such as artificial intelligence, mixed reality and biosensing to address neurological conditions such as stroke, and Alzheimer’s and Parkinson’s diseases. It has already cleared FDA and CE marks across multiple products.
The capital will drive international growth, accelerate research and development activities and allow MindMaze to consolidate its clinical development pipeline. In conjunction with the funding round, MindMaze has entered into a partnership with American Hospital Association.
Tej Tadi, founder and chief executive of MindMaze,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
